These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 9563885

  • 21. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL.
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [Abstract] [Full Text] [Related]

  • 22. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
    Lee EY, Cibull ML, Strodel WE, Haley JV.
    Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
    [Abstract] [Full Text] [Related]

  • 23. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [Abstract] [Full Text] [Related]

  • 24. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.
    Cancer Res; 2006 Aug 15; 66(16):8266-73. PubMed ID: 16912207
    [Abstract] [Full Text] [Related]

  • 25. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S, Wang J, Bourne P, Yang Q, Tang P.
    Ann Clin Lab Sci; 2007 Aug 15; 37(2):127-34. PubMed ID: 17522367
    [Abstract] [Full Text] [Related]

  • 26. HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
    Brown RE.
    Ann Clin Lab Sci; 2002 Aug 15; 32(1):12-21. PubMed ID: 11848612
    [Abstract] [Full Text] [Related]

  • 27. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
    Shien T, Tashiro T, Omatsu M, Masuda T, Furuta K, Sato N, Akashi-Tanaka S, Uehara M, Iwamoto E, Kinoshita T, Fukutomi T, Tsuda H, Hasegawa T.
    J Clin Pathol; 2005 Dec 15; 58(12):1299-304. PubMed ID: 16311351
    [Abstract] [Full Text] [Related]

  • 28. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD.
    J Surg Res; 2007 Jul 15; 141(1):53-9. PubMed ID: 17574038
    [Abstract] [Full Text] [Related]

  • 29. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
    Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB.
    Mol Cancer Res; 2004 Nov 15; 2(11):606-19. PubMed ID: 15561777
    [Abstract] [Full Text] [Related]

  • 30. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
    Cancer; 2003 Dec 15; 98(12):2547-53. PubMed ID: 14669272
    [Abstract] [Full Text] [Related]

  • 31. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L.
    Cancer; 2005 Feb 15; 103(4):830-8. PubMed ID: 15641030
    [Abstract] [Full Text] [Related]

  • 32. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD, Karlan BY.
    J Soc Gynecol Investig; 1996 Feb 15; 3(3):99-105. PubMed ID: 8796816
    [Abstract] [Full Text] [Related]

  • 33. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Schippinger W, Dandachi N, Regitnig P, Hofmann G, Balic M, Neumann R, Samonigg H, Bauernhofer T.
    Am J Clin Pathol; 2007 Oct 15; 128(4):630-7. PubMed ID: 17875515
    [Abstract] [Full Text] [Related]

  • 34. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
    Dabbs DJ.
    Mod Pathol; 1995 Aug 15; 8(6):637-42. PubMed ID: 8532697
    [Abstract] [Full Text] [Related]

  • 35. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R, Sastre G, Serrano J, Hunter Mellado R.
    Cell Mol Biol (Noisy-le-grand); 2001 Sep 15; 47(6):1025-32. PubMed ID: 11785652
    [Abstract] [Full Text] [Related]

  • 36. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
    Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL.
    Cancer; 2004 May 15; 100(10):2084-92. PubMed ID: 15139049
    [Abstract] [Full Text] [Related]

  • 37. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 38. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G.
    Gynecol Oncol; 2002 May 01; 85(2):305-10. PubMed ID: 11972392
    [Abstract] [Full Text] [Related]

  • 39. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 40. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ.
    Anticancer Res; 1996 Sep 07; 16(5B):3141-7. PubMed ID: 8920782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.